CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine could shield transplant patients from deadly virus
⭐️ VACCINE ⭐️ OngoingThis study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated May 19, 2026 12:01 UTC
-
New drug combo shows promise in controlling Early-Stage leukemia
Disease control OngoingThis study tests whether combining two drugs, dasatinib and venetoclax, can better control early chronic phase chronic myeloid leukemia (CML). About 155 adults with newly diagnosed CML will take these pills to block cancer cell growth. The goal is to reduce leukemia cells to very…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:59 UTC
-
New vaccine aims to shield transplant patients from deadly virus
Disease control OngoingThis study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
Immunotherapy boost may wipe out stubborn leukemia traces
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard targeted therapy (TKIs) can eliminate leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with stable disease but persistent low-level cancer markers will receive t…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
New combo therapy aims to squash stubborn leukemia cells
Disease control OngoingThis study tests whether adding ruxolitinib to standard tyrosine kinase inhibitors (TKIs) can further lower leukemia levels in people with chronic myeloid leukemia (CML) who still have detectable disease. About 81 adults with chronic-phase CML will receive either a TKI alone or a…
Matched conditions: CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 19, 2026 11:47 UTC